S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Paracetamol alone, paracetamol plus codeine, or paracetamol plus dihydrocodeine compared with placebo for neuropathic pain 
B A C K G R O U N D
This review is based on a template for reviews of drugs used to relieve neuropathic pain. The aim is for all reviews to use the same methods, based on new criteria for what constitutes reliable evidence in chronic pain (Moore 2010a; Moore 2012 ; Appendix 1).
Description of the condition
The 2011 International Association for the Study of Pain definition of neuropathic pain is "pain caused by a lesion or disease of the somatosensory system" (Jensen 2011), and based on a definition agreed at an earlier consensus meeting (Treede 2008) . Neuropathic pain is a consequence of a pathological maladaptive response of the nervous system to 'damage' from a wide variety of potential causes. It is characterised by pain in the absence of a noxious stimulus and may be spontaneous (continuous or paroxysmal) in its temporal characteristics or be evoked by sensory stimuli (dynamic mechanical allodynia where pain is evoked by light touch of the skin). Neuropathic pain is associated with a variety of sensory loss (numbness) and sensory gain (allodynia) clinical phenomena, the exact pattern of which vary between people and disease, perhaps reflecting different pain mechanisms operating in an individual person and, therefore, potentially predictive of response to treatment (Demant 2014; Helfert 2015; von Hehn 2012) . Preclinical research hypothesises a bewildering array of possible pain mechanisms that may operate in people with neuropathic pain, which largely reflect pathophysiological responses in both the central and peripheral nervous systems, including neuronal interactions with immune cells (Baron 2012; Calvo 2012; von Hehn 2012) . Overall, the treatment gains in neuropathic pain, to even the most effective of available drugs, are modest (Finnerup 2015; Moore 2013a) , and a robust classification of neuropathic pain is not yet available (Finnerup 2013) . Neuropathic pain is usually divided according to the cause of nerve injury. There may be many causes, but some common causes of neuropathic pain include diabetes (painful diabetic neuropathy (PDN)), shingles (postherpetic neuralgia (PHN)), amputation (stump and phantom limb pain), neuropathic pain after surgery or trauma, stroke or spinal cord injury, trigeminal neuralgia, and HIV infection. Sometimes the cause is unknown. Many people with neuropathic pain conditions are significantly disabled with moderate or severe pain for many years. Chronic pain conditions comprised five of the 11 top-ranking conditions for years lived with disability in 2010 (Vos 2012), and are responsible for considerable loss of quality of life and employment, and increased healthcare costs (Moore 2014a) . In systematic reviews, the overall prevalence of neuropathic pain in the general population is reported to be between 7% and 10% (van Hecke 2014), and about 7% in a systematic review of studies published since 2000 (Moore 2014a The proportion of people who achieve worthwhile pain relief (typically at least 50% pain intensity reduction; Moore 2013b) is small, generally only 10% to 25% more than with placebo, with numbers needed to treat for an additional beneficial outcome (NNT) usually between 4 and 10 (Kalso 2013; Moore 2013a). Neuropathic pain is not particularly different from other chronic pain conditions in that only a small proportion of trial participants have a good response to treatment (Moore 2013a (Norris 2008) . One study evaluating all cases of acute liver failure leading to registration for transplantation (ALFT) across seven European countries for a three-year period showed that paracetamol overdose was responsible for one sixth of cases of ALFT, though this varied considerably between each country (Gulmez 2015). Acute paracetamol hepatotoxicity at therapeutic doses has been judged to be extremely unlikely, despite reports of so-called 'therapeutic misadventure' . However, it has been observed that nonoverdose ALFT is more likely to follow therapeutic-dose paracetamol exposure than similar NSAID exposure (Gulmez 2013). Legislative changes have been introduced in the UK to restrict pack sizes and the maximum number of tablets permitted in nonprescription sales (CSM 1997) on the basis of evidence that poisoning is lower in countries that restrict availability (Gunnell 1997; Hawton 2001) . The contribution of these changes, which were inconvenient and costly (particularly to people with chronic pain), to any observed reductions in incidence of liver failure or death, remains uncertain (Bateman 2014a; Bateman 2014b; Hawkins 2007; Hawton 2013) . There have been concerns over the safety of paracetamol in people with compromised hepatic function (people with severe alcoholism, cirrhosis, or hepatitis), but these have not been substantiated (Dart 2000; PIC 2015) . The use of paracetamol during pregnancy has been questioned following reports that it is linked to behavioural problems and hyperkinetic disorders in children whose mothers took it during pregnancy (Liew 2014), and suggestions that it can interfere with sex hormones (Mazaud-Guittot 2013) .
In an analysis of single dose studies in migraine, there was no evidence that adverse events were more common with paracetamol 1000 mg than with placebo, and no serious adverse events occurred with paracetamol alone (Derry 2013b). Oral paracetamol has long been used as a first-line analgesic for a variety of acute and chronic conditions. It has modest efficacy in acute pain and migraine (Derry 2013b; Toms 2008) , although some randomised trials, systematic reviews, and meta-analyses have suggested that there is no good evidence for a clinically relevant benefit of paracetamol (as monotherapy) in many chronic pain conditions such as osteoarthritis and back pain (Machado 2015; Moore 2014d; Williams 2014). There are few or no data for a range of other common painful conditions, including dysmenorrhoea and neck pain. Moreover, accumulating evidence from observational studies indicates a considerable degree of paracetamol toxicity, especially at the upper end of standard analgesic doses (Roberts 2016) .
Oral paracetamol in fixed-dose combination with codeine or dihydrocodeine are frequently used in treating people with neuropathic pain (Hall 2013). There is good evidence showing that paracetamol plus codeine combinations are effective in acute pain (Toms 2009), but limited evidence for cancer pain (Straube 2014) . Dihydrocodeine was not effective in acute postoperative pain (Moore 2000) , and there is very little evidence on its efficacy in other pain conditions. Codeine is not effective in acute postoperative pain (Derry 2010). There is current uncertainty about the efficacy of opioids in chronic noncancer pain because of the influence of imputation methods where there are high levels of participant withdrawals in trials, and also in clinical practice. Reviews of oxycodone and buprenorphine for neuropathic pain have found no evidence of efficacy (Gaskell 2014; Wiffen 2015) .
How the intervention might work Paracetamol
The lack of significant anti-inflammatory activity of paracetamol implies a mode of action distinct from that of NSAIDs; yet, despite years of use and research, the mechanisms of action of paracetamol are not fully understood. NSAIDs act by inhibiting the activity of cyclo-oxygenase (COX), now recognised to consist of two isoforms (COX-1 and COX-2), which catalyses the production of prostaglandins responsible for pain and inflammation. Paracetamol has previously been shown to have no significant effects on COX-1 or COX-2 ( 
Codeine and dihydrocodeine
Codeine and dihydrocodeine are opioids. The analgesic effects of codeine are attributed to its metabolism in the liver to the active compounds morphine and morphine-6-glucuronide. Normally between 5% and 10% is converted to morphine, and a dose of codeine phosphate of about 30 mg is considered equivalent to morphine 3 mg. However, the capacity to metabolise codeine to its active metabolites varies between people, with up to 10% of white people, 2% of Asian people, and 1% of Arabic people being 'poor metabolisers'. In these people, codeine is a relatively ineffective analgesic. The enzyme CYP2D6 is a member of the cytochrome P450 mixed-function oxidase system enzymes, and one of the most important enzymes involved in the metabolism of xenobiotics in the body. Due to genetic variability in the CYP2D6 enzyme, up to 40% of people in some societies are 'ultra-metabolisers' and are able to convert more of the codeine to morphine, putting them at increased risk of toxicity from standard doses (Sistonen 2007) . Various medications interfere with the enzymes that catalyse the metabolism of codeine, increasing or decreasing the extent of conversion and hence the analgesic effect. For example, the selective serotonin reuptake inhibitors fluoxetine and paroxetine reduce conversion, while rifampicin and dexamethasone increase it. The US and Canada issued warnings about the potentially life-threatening adverse effects in infants of breastfeeding mothers taking codeine, in 2007 (US) and 2008 (Canada), and this has led to reductions in codeine use in the postpartum period (Smolina 2015) . Dihydrocodeine is a synthetic opioid analgesic developed in the early 1900s. Its structure and pharmacokinetics are similar to that of codeine (Rowell 1983) , and it has been infrequently used for the treatment of postoperative pain or as an antitussive. Dihydrocodeine analgesia seems not to be linked to metabolism through CYP2D6 activity, because the parent compound has analgesic effects, there are multiple metabolic pathways, and there is a limited role of dihydromorphine (Leppert 2016).
Why it is important to do this review
Paracetamol, alone or in fixed dose combination with codeine or dihydrocodeine, was one of the most commonly used first-line treatments for neuropathic pain conditions such as PHN (27% of patients), PDN (17%), neuropathic low back pain (37%), or even phantom limb pain (13%) (Hall 2013). We found no previous review of paracetamol or paracetamol in combination with opioids for treating neuropathic pain. Paracetamol combined with an opioid is considered a reasonable treatment for breakthrough pain occurring with neuropathic pain treatment in one Canadian guideline (Moulin 2014 ), but it is not suggested as a treatment in other guidelines (NICE 2013) or reviews (Finnerup 2015) . The standards used to assess evidence in chronic pain trials have changed substantially in recent years, with particular attention being paid to trial duration, withdrawals, and statistical imputation following withdrawal, all of which can substantially alter estimates of efficacy. The most important change is the move from using mean pain scores, or mean change in pain scores, to the number of people who have a large decrease in pain (by at least 50%) and who continue in treatment, ideally in trials of 8 to 12 weeks' duration or longer. Pain intensity reduction of 50% or more correlates with improvements in comorbid symptoms, function, and quality of life generally (Moore 2013a) , and in people with neuropathic pain (Hoffman 2010). These standards are set out in the PaPaS Author and Referee Guidance for pain studies of the Cochrane Pain, Palliative and Supportive Care Group (PaPaS 2012). This Cochrane review assessed evidence using methods that make both statistical and clinical sense, using developing criteria for what constitutes reliable evidence in chronic pain (Moore 2010a) . Trials included and analysed must have met a minimum of reporting quality (blinding, randomisation), validity (duration, dose and timing, diagnosis, outcomes, etc.), and size. Ideally at least 500 participants are needed in a comparison in which the NNT is 4 or above to measure the magnitude of a treatment effect adequately (Moore 1998 ). This approach sets high standards for the demonstration of efficacy and marks a departure from how reviews were conducted previously.
O B J E C T I V E S
To assess the analgesic efficacy and adverse events of paracetamol with or without codeine or dihydrocodeine for chronic neuropathic pain in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to include randomised controlled trials (RCTs) with double-blind assessment of participant outcomes following two weeks or more of treatment, although the emphasis of the review was on studies with a duration of eight weeks or longer. We required full journal publication, except for online clinical trial results summaries of otherwise unpublished clinical trials and abstracts with sufficient data for analysis. We excluded short abstracts (usually meeting reports). We excluded studies that were nonrandomised, studies of experimental pain, case reports, and clinical observations.
Types of participants
Studies included adults aged 18 years and above with one or more chronic neuropathic pain condition including (but not limited to): 1. cancer-related neuropathy; 2. central neuropathic pain; 3. complex regional pain syndrome (CRPS) Type II; 4. HIV neuropathy; 5. painful diabetic neuropathy (PDN); 6. phantom limb pain; 7. postherpetic neuralgia (PHN); 8. postoperative or traumatic neuropathic pain; 9. spinal cord injury; 10. trigeminal neuralgia. We planned to analyse included studies of participants with more than one type of neuropathic pain according to the primary condition.
Types of interventions
Oral paracetamol with or without codeine or dihydrocodeine, at any dose, administered for the relief of neuropathic pain and compared with placebo or any active comparator.
Types of outcome measures
We anticipated that studies would use a variety of outcome measures, with most studies using standard subjective scales (numerical rating scale or visual analogue scale) for pain intensity or pain relief, or both. We were particularly interested in Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) definitions for moderate and substantial benefit in chronic pain studies (Dworkin 2008) . These are defined as:
1. at least 30% pain relief over baseline (moderate); 2. at least 50% pain relief over baseline (substantial); 3. much or very much improved on Patient Global Impression of Change scale (PGIC; moderate); 4. very much improved on PGIC (substantial). These outcomes are different from those used in most earlier reviews, concentrating as they do on dichotomous outcomes where pain responses do not follow a normal (Gaussian) distribution.
People with chronic pain desire high levels of pain relief, ideally more than 50% pain intensity reduction, and ideally having no worse than mild pain (Moore 2013a; O'Brien 2010) .
Primary outcomes
1. Participant-reported pain relief of 30% or greater. 2. Participant-reported pain relief of 50% or greater. 3. PGIC much or very much improved. 4. PGIC very much improved.
Secondary outcomes
1. Any pain-related outcome indicating some improvement. 2. Withdrawals due to lack of efficacy, adverse events, and for any cause.
3. Participants experiencing any adverse event.
4. Participants experiencing any serious adverse event. Serious adverse events typically include any untoward medical occurrence or effect that at any dose results in death, is lifethreatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, is an 'important medical event' that may jeopardise the patient, or may require an intervention to prevent one of the above characteristics or consequences.
5. Specific adverse events, particularly somnolence and dizziness.
Search methods for identification of studies Electronic searches
We searched the following databases, without language restrictions:
1. Cochrane Central Register of Controlled Trials (CENTRAL; via CRSO) on 7 July 2016; 2. MEDLINE (via Ovid) from 1946 to 7 July 2016; 3. Embase (via Ovid) from 1974 to 7 July 2016; 4. Oxford Pain Relief Database (Jadad 1996a). The search strategies for CENTRAL, MEDLINE, and Embase are in Appendix 3, Appendix 4, and Appendix 5, respectively.
Searching other resources
We reviewed the bibliographies of any RCTs identified and review articles, and searched clinical trial databases (ClinicalTrials.gov and World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (apps.who.int/trialsearch/)) to identify additional published or unpublished data (to 7 June 2016). We did not plan to contact investigators or study sponsors.
Data collection and analysis
We planned to perform separate analyses according to particular neuropathic pain conditions. We planned to combine different neuropathic pain conditions in analyses for exploratory purposes only. We planned to perform analyses separately for paracetamol alone, paracetamol plus codeine, and paracetamol plus dihydrocodeine according to daily dose of drug used.
Selection of studies
We determined eligibility by reading the abstract of each study identified by the search. We eliminated studies that clearly did not satisfy the inclusion criteria, and we obtained full copies of the remaining studies for further consideration. Two review authors (RAM and SD) read studies independently and reached agreement by discussion. We did not anonymise the studies before assessment. We have provided a PRISMA flow chart.
Data extraction and management
Two review authors (RAM, SD) planned to extract data independently using a standard form and check for agreement before entry into Review Manager 5 (RevMan 2014), or any other analysis tool. We resolved disagreements by discussion, involving a third review author (PW), if necessary. We planned to include information about the pain condition and number of participants treated, drug and dosing regimen, study design (placebo or active control), study duration and follow-up, analgesic outcome measures and results, withdrawals, and adverse events (participants experiencing any adverse event, or serious adverse event).
Assessment of risk of bias in included studies
We planned to use the Oxford Quality Score as the basis for inclusion (Jadad 1996b), limiting inclusion to studies that were randomised and double-blind as a minimum. Two review authors (SD, RAM) planned to independently assessed risk of bias for each study, using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Chapter 8, Higgins 2011), and adapted from those used by the Cochrane Pregnancy and Childbirth Group, with any disagreements resolved by discussion. We assessed the following for each study.
1. Random sequence generation (checking for possible selection bias). We planned to assess the method used to generate the allocation sequence as: low risk of bias (any truly random process: random number table; computer random number generator); unclear risk of bias (when the method used to generate the sequence was not clearly stated). We planned to exclude studies at a high risk of bias that used a nonrandom process (odd or even date of birth; hospital or clinic record number).
2. Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We planned to assess the methods as: low risk of bias (telephone or central randomisation; consecutively numbered, sealed, opaque envelopes); unclear risk of bias (when the method was not clearly stated). We planned to exclude studies that did not conceal allocation and were therefore at a high risk of bias (open list).
3. Blinding of participants and personnel (checking for possible performance bias), and blinding of outcome assessment (checking for possible detection bias). We planned to assess the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We planned to assess the methods as: low risk of bias (study stated that it was blinded and described the method used to achieve blinding, used identical tablets, matched in appearance and smell); unclear risk of bias (study stated that it was blinded but did not provide an adequate description of how it was achieved). We planned to exclude studies at a high risk of bias that were not double-blind.
4. Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk of bias (fewer than 10% of participants did not complete the study or used 'baseline observation carried forward' analysis, or both); unclear risk of bias (used 'last observation carried forward' (LOCF) analysis); or high risk of bias (used 'completer' analysis).
5. Size of study (checking for possible biases confounded by small size). We planned to assess studies as being at low risk of bias (200 participants or more per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); or high risk of bias (fewer than 50 participants per treatment arm).
Measures of treatment effect
We planned to calculate the number needed to treat for an additional beneficial outcome (NNT) as the reciprocal of the absolute risk reduction (ARR; McQuay 1998). For unwanted effects, the number needed to treat becomes the number needed to treat for an additional harmful outcome (NNH) and is calculated in the same manner. We planned to use dichotomous data to calculate risk ratio (RR) with 95% confidence intervals (CI) using a fixedeffect model unless we found significant statistical heterogeneity (see Data synthesis). We would not use continuous data in analyses.
Unit of analysis issues
We planned to split the control treatment arm between active treatment arms in a single study if the active treatment arms were not combined for analysis. We did not anticipate that any crossover studies would be included, as they are usually of short duration.
Dealing with missing data
We planned to use intention-to-treat (ITT) analysis where the ITT population consisted of participants who were randomised, took at least one dose of the assigned study medication, and provided at least one postbaseline assessment. We planned to assign missing participants as zero improvement wherever possible.
Assessment of heterogeneity
We planned to deal with clinical heterogeneity by combining studies that examined similar conditions. We planned to assess statistical heterogeneity visually (L'Abbé 1987) , and with the use of the I 2 statistic. If the I 2 value was greater than 50%, we planned to consider possible reasons for this.
Assessment of reporting biases
The aim of this review was to use dichotomous outcomes of known utility and of value to people with neuropathic pain (Hoffman 2010; Moore 2010b; Moore 2010c; Moore 2010d; Moore 2013a). The review did not depend on what the authors of the original studies chose to report or not. We would have extracted and used continuous data, which probably will reflect efficacy and utility poorly, if useful for illustrative purposes only. We planned to assess publication bias using a method designed to detect the amount of unpublished data with a null effect required to make any result clinically irrelevant (usually taken to mean a NNT of 10 or higher in this condition; Moore 2008).
Data synthesis
We planned to use a fixed-effect model for meta-analysis. We would use a random-effects model for meta-analysis if there was significant clinical heterogeneity and it was considered appropriate to combine studies.
Quality of evidence
We planned to use the GRADE system to assess the quality of the evidence related to the key outcomes listed in Types of outcome measures, as appropriate (Appendix 5; Chapter 12, Higgins 2011). At least two review authors planned to independently rated the quality of evidence for each outcome. We planned to assess potential for publication bias, based on the amount of unpublished data required to make the result clinically irrelevant . In addition, there may be circumstances where the overall rating for a particular outcome needs to be adjusted as recommended by GRADE guidelines (Guyatt 2013a). For example, if there are so few data that the results are highly susceptible to the random play of chance, or if studies use LOCF imputation in circumstances where there are substantial differences in adverse event withdrawals, one would have no confidence in the result, and would need to downgrade the quality of the evidence by three levels, to very low quality. In circumstances where there were no data reported for an outcome, we planned to report the level of evidence as very low quality (Guyatt 2013b). We would also consider any other factors while making GRADE assessments.
'Summary of findings' table
We planned to include a 'Summary of findings' table as set out in the Pain, Palliative and Supportive Care Group (PaPaS) author guide (PaPaS 2012), and recommended in the Cochrane Handbook for Systematic Reviews of Interventions, Section 4.6.6 (Higgins 2011). The table would have included outcomes equivalent to moderate benefit (at least 30% pain intensity reduction or PGIC much or very much improved, or both) and substantial benefit (at least 50% pain intensity reduction or PGIC very much improved, or both), withdrawals due to lack of efficacy, withdrawals due to adverse events, serious adverse events, and death (a particular serious adverse event). For the 'Summary of findings' table we used the following descriptors for levels of evidence (EPOC 2015).
• High: This research provides a very good indication of the likely effect. The likelihood that the effect will be substantially different † is low.
• Moderate: This research provides a good indication of the likely effect. The likelihood that the effect will be substantially different † is moderate.
• Low: This research provides some indication of the likely effect. However, the likelihood that it will be substantially different † is high.
• Very low: This research does not provide a reliable indication of the likely effect. The likelihood that the effect will be substantially different † is very high. † Substantially different: a large enough difference that it might affect a decision.
Subgroup analysis and investigation of heterogeneity
We planned all analyses to be according to individual painful conditions, because placebo response rates for the same outcome can vary between conditions, as can the drug-specific effects (Moore 2009 ). Possible issues for subgroup analysis might be dose, formulation, and route of administration. A minimum of two studies and 200 participants were required for any subgroup analysis.
Sensitivity analysis
We planned no sensitivity analysis because the evidence base is known to be too small to allow reliable analysis.
R E S U L T S Description of studies

Results of the search
The searches of CENTRAL, MEDLINE, and Embase identified 1127 records; 1126 of these clearly did not satisfy the inclusion criteria. We read the full text of the one remaining record for possible inclusion and excluded it (Palangio 2000). Searches of clinical trials databases did not identify any relevant ongoing or unpublished studies (see Figure 1) . 
Included studies
No studies satisfied our inclusion criteria.
Excluded studies
We excluded one study (Palangio 2000) . This was a randomised, double-blind comparison of paracetamol plus codeine with ibuprofen plus hydrocodone over four weeks in 469 participants with chronic pain. Of these, three participants had diabetic neuropathy, five had PHN, and 21 had other neurological chronic pain; most participants had chronic musculoskeletal pain. Results for these actual and possible neuropathic pain conditions were not presented separately.
Risk of bias in included studies
We did not assess risk of bias as there were no included studies.
Effects of interventions
See: Summary of findings for the main comparison Paracetamol alone, paracetamol plus codeine, or paracetamol plus dihydrocodeine compared with placebo for neuropathic pain We found no studies satisfying our inclusion criteria. We have only very low quality evidence and are very uncertain about estimates of benefit and harm.
D I S C U S S I O N
Summary of main results
We found no RCTs assessing the beneficial or harmful effects of paracetamol alone, or in combination with codeine or dihydrocodeine, in the treatment of any type of neuropathic pain; only very low quality evidence was available. This is despite paracetamol, alone or in fixed dose combination with codeine or dihydrocodeine, being one of the most commonly used first-line treatments for neuropathic pain conditions such as PHN, PDN, neuropathic low back pain, or phantom limb pain (Hall 2013) . The absence of evidence for efficacy probably explains why these treatments do not feature in neuropathic pain guidelines.
Overall completeness and applicability of evidence
There is no evidence from randomised, double-blind, comparative studies to support or refute the use of paracetamol alone, or combined with codeine or dihydrocodeine, for the treatment of neuropathic pain. One excluded study had only a trivial number of participants with neuropathic pain and did not report on them separately (Palangio 2000) . During our searches, we found no large body of evidence with other study designs, such as open comparative studies, or observational studies, other than one case report of one patient given intravenous paracetamol (Gulcu 2007) . There are only small amounts of evidence for combinations of paracetamol with other opioids. For paracetamol combinations with tramadol, we identified a single randomised, doubleblind, placebo-controlled study of modest size (160 participants) (Freeman 2007) , an open randomised study (Ko 2010) , and a cohort study (Danilov 2007) , all in the treatment of PDN. We also found a single observational study of paracetamol plus oxycodone (Gatti 2009). While our searches were not designed to find all studies with paracetamol combined with opioids, the absence of a significant body of evidence is confirmed by other reviews (Finnerup 2015) . The main importance is the stark contrast between widespread use of paracetamol, with or without codeine or dihydrocodeine, in neuropathic pain, and absence of evidence of efficacy. This is especially important at a time when the efficacy of paracetamol in other chronic pain conditions is being challenged. Paracetamol alone is no better than placebo for low back pain (Saragiotto 2016 ), spinal pain, or osteoarthritis (Machado 2015 , and its use has been challenged in cancer pain (Mercadante 2013) . The assumed safety of paracetamol is also being challenged (Roberts 2016) .
Quality of the evidence
We found no RCTs.
Potential biases in the review process
We know of no potential biases in the review process. It is unlikely that there is a large body of unpublished evidence showing a large effect from paracetamol alone or in combination with codeine or dihydrocodeine in neuropathic pain.
Agreements and disagreements with other studies or reviews
We identified no other relevant reviews. A wide-ranging review of drug therapies for neuropathic pain also found no relevant trials (Finnerup 2015) , as did a Cochrane Review on combination pharmacotherapy (Chaparro 2012).
A U T H O R S ' C O N C L U S I O N S
Implications for practice For people with neuropathic pain
There is insufficient evidence to support or refute the suggestion that paracetamol, alone or in combination with codeine or dihydrocodeine, has any efficacy in any neuropathic pain condition.
For clinicians
For policy makers
There is insufficient evidence to support or refute the suggestion that paracetamol, alone or in combination with codeine or dihydrocodeine, has any efficacy in any neuropathic pain condition. It should be noted that there is evidence of lack of effect of paracetamol alone in other chronic pain conditions. In the absence of any supporting evidence, these drugs should probably not be recommended, except at the discretion of a pain specialist.
For funders
There is insufficient evidence to support or refute the suggestion that paracetamol, alone or in combination with codeine or dihydrocodeine, has any efficacy in any neuropathic pain condition. It should be noted that there is evidence of lack of effect of paracetamol alone in other chronic pain conditions.
Implications for research
Large, robust randomised trials with patient-centred outcomes would be required to produce evidence to support or refute efficacy of paracetamol, alone or in combination with codeine or dihydrocodeine, in neuropathic pain. The necessary design of such trials is well established, but, for opioids in neuropathic pain, the outcomes should be those of at least 30% and at least 50% pain intensity reduction over baseline at the end of a trial of 12 weeks' duration in participants continuing on treatment. Withdrawal for any reason should be regarded as treatment failure, and last observation carried forward (LOCF) analysis should not be used. This is because, in chronic pain, opioids frequently produce withdrawal rates of 50% or more, meaning that LOCF analysis can overstate treatment efficacy to a large extent.
Given the knowledge that paracetamol is proven to be without effect or has no evidence to support efficacy in any chronic pain condition, the value of such trials would be questionable. The protocol followed the agreed template for neuropathic pain, which was developed in collaboration with the Cochrane Musculoskeletal Group and Cochrane Neuromuscular Diseases Group. The editorial process was managed by the Cochrane Pain, Palliative and Supportive Care Group.
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C O N T R I B U T I O N S O F A U T H O R S
SD and RAM wrote the protocol, though this was based on a template that had previously been the subject of input from many sources, and which has been subject to extensive peer review.
SD and RAM searched for and selected studies for inclusion.
All review authors were involved in writing the full review.
PW will be responsible for any updates required. PC received support from Boston Scientific (2014) for travel and accommodation at a scientific meeting; Boston Scientific does not market paracetamol products. PC is a specialist pain physician and manages patients with chronic pain.
D E C L A R A T I O N S O F I N T E R E S T
TP: none known; TP is a specialist pain physician and manages patients with neuropathic pain.
RAM has received grant support from RB relating to individual patient level analyses of trial data on ibuprofen in acute pain and the effects of food on drug absorption of analgesics (2013), and from Grünenthal relating to individual patient level analyses of trial data regarding tapentadol in osteoarthritis and back pain (2015) . He has received honoraria for attending boards with Menarini concerning methods of analgesic trial design (2014), with Novartis (2014) about the design of network meta-analyses, and RB on understanding pharmacokinetics of drug uptake (2015).
